All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM ~1.5:1 split | DEC 2025 ~1.3:1 split | DEC 2024 | DEC 2023 | DEC 2022 ~2.6:1 split | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $2 | $2 | $0 | – | – | – |
| Cost of Revenue | $13 | $10 | $0 | – | – | – |
| Gross Profit | -$10 | -$8 | $0 | – | – | – |
| General & Administrative | $31 | $31 | $26 | $23 | $23 | $21 |
| Research & Development | $69 | $69 | $89 | $77 | $63 | $61 |
| Total Operating Expenses | $113 | $110 | $114 | $100 | $86 | $82 |
| Operating Income | -$111 | -$108 | -$114 | -$100 | -$85 | -$81 |
| Non-Operating | ||||||
| Net Interest Expense | -$8 | -$9 | -$5 | -$1 | -$4 | -$4 |
| Other Non-Operating Income (Expense) | $14 | $76 | -$34 | -$11 | $73 | $55 |
| EBT (Earnings Before Tax) | – | -$41 | – | – | – | – |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$97 | -$41 | -$149 | -$111 | -$12 | -$26 |
| Per Share Data | ||||||
| Revenue Per Share | $0.01 | $0.01 | $0.00 | – | – | – |
| EPS (Basic) | -$0.55 | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 |
| EPS (Diluted) | -$0.55 | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 |
| Weighted Avg Shares (Basic) | 234.2M | 158.2M | 118.5M | 103.4M | 103.1M | 40.0M |
| Weighted Avg Shares (Diluted) | 234.2M | 158.2M | 118.5M | 103.4M | 103.1M | 40.0M |
| Shares Outstanding | 234.2M | 158.2M | 118.5M | 103.4M | 103.1M | 40.0M |
Humacyte (HUMA) financials: revenue, profit and margins
Humacyte (HUMA) generated about $2 million in revenue and -$97 million in net income (a -4,560.8% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Humacyte's (HUMA) revenue?+
Humacyte generated about $2 million in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Humacyte profitable?+
Humacyte reported about -$97 million in net loss over the trailing twelve months, a net margin of roughly -4,560.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Humacyte's profit margins?+
Humacyte runs a gross margin of about -494.6%, an operating margin of about -5,240.8%, a net margin of about -4,560.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
SourceFinancial statements computed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with HUMA
Held by ETFs
HUMA is in 4 US ETFs. The largest of them, with HUMA's weight in each:
Spot a number that looks wrong? Check it in HUMA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HUMA
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.